Edwards Lifesciences Reports Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences (EW) PT, Estimates Lifted at Piper Jaffray Amid Solid Q2
July 29, 2015 9:02 AM EDTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted estimates and his price target on Edwards Lifesciences (NYSE: EW) to $181.00 (from $170.00) following Q2 results.
West commented, "Edwards reported Q2 revenues of $616.8M, beating our Street high estimate of $615.5M and consensus... More
Edwards Lifesciences (EW) Tops Q2 EPS by 8c; Lifts FY15 Outlook
July 28, 2015 4:38 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.13, $0.08 better than the analyst estimate of $1.05. Revenue for the quarter came in at $616.8 million versus the consensus estimate of $604.97 million.
"Strong performance this quarter was boosted by growing global TAVR therapy adoption, with our transcatheter heart... More
